Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 816

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Subclonal diversification of primary breast cancer revealed by multiregion sequencing

Open access
Yates, Lucy R, Gerstung, Moritz, Knappskog, Stian, Desmedt, Christine, Gundem, Gunes, Van Loo, Peter, Aas, Turid, Alexandrov, Ludmil B, Larsimont, Denis, Davies, Helen, Li, Yilong, Ju, Young Seok, Ramakrishna, Manasa, Haugland, Hans Kristian, Lilleng, Peer Kaare, Nik-Zainal, Serena, McLaren, Stuart, Butler, Adam, Martin, Sancha, Glodzik, Dominic, Menzies, Andrew, Raine, Keiran, Hinton, Jonathan, Jones, David, Mudie, Laura J, Jiang, Bing, Vincent, Delphine, Greene-Colozzi, April, Adnet, Pierre-Yves, Fatima, Aquila, Maetens, Marion, Ignatiadis, Michail, Stratton, Michael R, Sotiriou, Christos, Richardson, Andrea L, Lønning, Per Eystein, Wedge, David C, Campbell, Peter J·2015·Nature Medicine

Abstract

The sequencing of cancer genomes may enable tailoring of therapeutics to the underlying biological abnormalities driving a particular patient's tumor. However, sequencing-based strategies rely heavily on representative sampling of tumors. To understand the subclonal structure of primary breast cancer, we applied whole-genome and targeted sequencing to multiple samples from each of 50 patients' tumors (303 samples in total). The extent of subclonal diversification varied among cases and followed spatial patterns. No strict temporal order was evident, with point mutations and rearrangements affecting the most common breast cancer genes, including PIK3CA, TP53, PTEN, BRCA2 and MYC, occurring early in some tumors and late in others. In 13 out of 50 cancers, potentially targetable mutations were subclonal. Landmarks of disease progression, such as resistance to chemotherapy and the acquisition of invasive or metastatic potential, arose within detectable subclones of antecedent lesions. These findings highlight the importance of including analyses of subclonal structure and tumor evolution in clinical trials of primary breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.3886

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 816

Metadata

Authors
Yates, L. R., Gerstung, M., Knappskog, S., Desmedt, C., Gundem, G., Van Loo, P., Aas, T., Alexandrov, L. B., Larsimont, D., Davies, H., Li, Y., Ju, Y. S., Ramakrishna, M., Haugland, H. K., Lilleng, P. K., Nik-Zainal, S., McLaren, S., Butler, A., Martin, S., Glodzik, D., Menzies, A., Raine, K., Hinton, J., Jones, D., Mudie, L. J., Jiang, B., Vincent, D., Greene-Colozzi, A., Adnet, P.-Y., Fatima, A., Maetens, M., Ignatiadis, M., Stratton, M. R., Sotiriou, C., Richardson, A. L., Lønning, P. E., Wedge, D. C., & Campbell, P. J.
Venue
Nature Medicine
Published
2015-06-22
Volume
21
Issue
7
Pages
751-759
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W1526705543
Cited by
816
References
13
FWCI
29.34
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.